These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 31196659)

  • 21. Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors.
    Dattolo PC; Gallo P; Michelassi S; Paudice N; Cannavò R; Romoli E; Fani F; Tsalouchos A; Mehmetaj A; Ferro G; Sisca S; Pizzarelli F
    J Nephrol; 2016 Dec; 29(6):809-815. PubMed ID: 27015900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of first-line antihypertensive drug classes on the maintenance of estimated glomerular filtration rate (eGFR) in real world primary care.
    Gao Q; Tan NC; Lee ML; Hsu W; Choo J
    Sci Rep; 2023 Dec; 13(1):21225. PubMed ID: 38040765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renin-angiotensin-aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial.
    García-Prieto AM; Verdalles Ú; de José AP; Arroyo D; Aragoncillo I; Barbieri D; Camacho RE; Goicoechea M
    Hipertens Riesgo Vasc; 2024; 41(2):95-103. PubMed ID: 38508877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Classical nephroprotection: Renin angiotensin aldosterone system inhibitors].
    Egocheaga MI; Drak Y; Otero V
    Semergen; 2023 Jun; 49 Suppl 1():102018. PubMed ID: 37355297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of renin angiotensin system inhibitors in patients with chronic kidney disease.
    Adam WR; Wright JR
    Intern Med J; 2016 May; 46(5):626-30. PubMed ID: 27170242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of renin-angiotensin-aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design.
    García-Prieto AM; Verdalles Ú; de José AP; Verde E; Arroyo D; Aragoncillo I; Linares T; Barbieri D; Goicoechea M
    Hipertens Riesgo Vasc; 2020; 37(3):101-107. PubMed ID: 32156479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renin-angiotensin system inhibitors for patients with mild or moderate chronic kidney disease and heart failure with mildly reduced or preserved ejection fraction.
    Takeuchi S; Kohno T; Goda A; Shiraishi Y; Kitamura M; Nagatomo Y; Takei M; Nomoto M; Soejima K; Kohsaka S; Yoshikawa T;
    Int J Cardiol; 2024 Aug; 409():132190. PubMed ID: 38761975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual renin-angiotensin system blockade for nephroprotection.
    Ruggenenti P
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.
    Čertíková Chábová V; Kujal P; Škaroupková P; Varňourková Z; Vacková Š; Husková Z; Kikerlová S; Sadowski J; Kompanowska-Jezierska E; Baranowska I; Hwang SH; Hammock BD; Imig JD; Tesař V; Červenka L
    Kidney Blood Press Res; 2018; 43(2):329-349. PubMed ID: 29529602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.
    Susantitaphong P; Sewaralthahab K; Balk EM; Eiam-ong S; Madias NE; Jaber BL
    Am J Hypertens; 2013 Mar; 26(3):424-41. PubMed ID: 23382494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction.
    Loutradis C; Price A; Ferro CJ; Sarafidis P
    J Hum Hypertens; 2021 Jun; 35(6):499-509. PubMed ID: 33654237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
    Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
    Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kidney Function After a Hypertensive Disorder of Pregnancy: A Longitudinal Study.
    Paauw ND; van der Graaf AM; Bozoglan R; van der Ham DP; Navis G; Gansevoort RT; Groen H; Lely AT
    Am J Kidney Dis; 2018 May; 71(5):619-626. PubMed ID: 29289477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of renin-angiotensin-aldosterone system blockade in controversial chronic kidney disease populations.
    García-Prieto AM; Verdalles Ú; Goicoechea M
    Med Clin (Barc); 2021 Jun; 156(11):561-567. PubMed ID: 33757646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal safety and survival among acutely ill hospitalized patients treated by blockers of the Renin-Angiotensin axis or loop diuretics: a single-center retrospective analysis.
    Assaly M; Gorelik Y; Heyman SN; Abassi Z; Khamaisi M
    Ren Fail; 2023; 45(2):2282707. PubMed ID: 37975172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study.
    Fu EL; Evans M; Clase CM; Tomlinson LA; van Diepen M; Dekker FW; Carrero JJ
    J Am Soc Nephrol; 2021 Feb; 32(2):424-435. PubMed ID: 33372009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesity, Renin-Angiotensin System Blockade and Risk of Adverse Renal Outcomes: A Population-Based Cohort Study.
    Cohen JB; Stephens-Shields AJ; Denburg MR; Anderson AH; Townsend RR; Reese PP
    Am J Nephrol; 2016; 43(6):431-40. PubMed ID: 27228992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors/angiotensin receptor blockers in patients with chronic kidney disease.
    Soares AE; Maes M; Godeny P; Matsumoto AK; Barbosa DS; da Silva TAF; Souza FHMO; Delfino VDA
    Life Sci; 2017 Dec; 191():175-179. PubMed ID: 29079468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.